论文部分内容阅读
为探讨苯那普利对阿霉素肾病幼鼠肾硬化的保护作用 ,将SD幼龄大鼠行单侧肾切除加阿霉素注射建立动物模型 ,术后即对治疗组大鼠给予苯那普利6mg/(kg·d)治疗12周 ,观察大鼠尿蛋白、血生化及残余肾组织的病理改变。结果 :苯那普利于治疗的第7、9、12周显示出较好降尿蛋白作用 ,尿蛋白与同期模型组相比分别为 (7.3±4.4)mg/24h、(2.0±1.2)mg/24h、(5.2±3.5)mg/24h比 (14.4±1.8)mg/24h、(17.5±9.8)mg/24h、(15.2±4.7)mg/24h(P均<0.01) ;形态学上显示系膜增生和肾小球硬化均减轻 ,与模型组相比系膜增生率和硬化指数分别为8.0(5.0～13.1) %比35.4(11.0～67.5) %和0.3(0.3～0.9)比1.9(0.3～6.7) (P均<0.05)。提示 ,在单侧肾切除加阿霉素注射的幼龄肾病大鼠肾硬化模型中 ,苯那普利显示了肾保护作用。
In order to investigate the protective effects of benazepril on nephrosclerosis in adriamycin-induced nephropathy rats, SD young rats were treated with unilateral nephrectomy and doxorubicin injection to establish an animal model. After treatment, rats in the treatment group were given Benazepril Puli 6mg / (kg · d) for 12 weeks to observe the pathological changes of urinary protein, blood biochemistry and residual renal tissue. Results: Benazepril showed better effect of reducing proteinuria on the 7th, 9th and 12th week of treatment. Urinary protein was (7.3 ± 4.4) mg / 24h, (2.0 ± 1.2) mg / 24h, 5.2 ± 3.5 mg / 24h, 14.4 ± 1.8 mg / 24h, 17.5 ± 9.8 mg / 24h and 15.2 ± 4.7 mg / 24h, respectively (5.0 ~ 13.1)% vs 35.4 (11.0 ~ 67.5)% and 0.3 (0.3 ~ 0.9) than 1.9 (0.3 ~ 0.9) respectively.Compared with the model group, the hyperplasia and glomerulosclerosis were all decreased 6.7) (P <0.05). This suggests that benazepril demonstrated renal protection in a model of nephrosclerosis in young kidneys injected with unilateral nephrectomy plus doxorubicin.